SH2D2A

Across TCGA pan-cancer cohorts, SH2D2A RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SH2D2A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SH2D2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SH2D2A is over-expressed in tumor.

HNSC, KIRC, and STAD are the cancer types where SH2D2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH2D2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+2.104	<.001	12	view →
KIRC	Male	IV	+1.885	<.001	12	view →
STAD	Female	All	+2.025	<.001	9	view →
COAD	Female	II,III,IV	+0.977	<.001	9	view →
BLCA	Male	III,IV	+2.020	.002	8	view →
UCEC	All	All	+0.940	<.001	8	view →
BRCA	All	All	+0.747	<.001	6	view →
KIRP	All	All	+0.691	<.001	6	view →
LUAD	All	All	+0.584	<.001	6	view →
ESCA	All	All	+1.896	<.001	5	view →
LUSC	Female	III,IV	+1.335	<.001	4	view →
LIHC	Female	II,III,IV	+0.730	.008	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SH2D2A–HNSC

Open the HNSC breakdown →